Explore All 810 Add-on Acquisition Test/Measurement Equipment Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | February 9, 2015 |
| Target | Saphymo SAS |
| Sector | Test/Measurement Equipment |
| Buyer(s) | Bertin Technologies |
| Sellers(s) | Edmond de Rothschild Private Equity |
| Deal Type | Add-on Acquisition |
FILTER BY
Bertin Technologies specializes in the development and integration of systems scientific instrumentation. Bertin Technologies is the historic preferred partner of customers in demanding fields: life sciences, nuclear detection, large instruments scientists, defense & security, space, medical waste treatment. Bertin Technologies was founded in 1956 and is based in Montigny-le-Bretonneux, France.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Test/Measurement Equipment | 1 of 1 |
| Type: Add-on Acquisition | 1 of 2 |
| Country: France | 1 of 1 |
| Year: 2015 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-31 |
Exensor Technology AB
Lund, Sweden Exensor Technology AB is a supplier of networked unattended ground sensor (UGS) systems to customers around the world. Exensor is based in Lund, Sweden. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2014 |
| PE ASSETS | 4.3B EUR |
| Size | Large |
| Type | Sector Agnostic |
Edmond de Rothschild Private Equity is the private equity arm of asset manager and financial services firm Edmond de Rothschild. The private equity group looks seeks buyout and expansion style investments and will consider opportunities across the world, including North America, Europe, and Africa. The Firm broadly invests in real estate, infrastructure projects, and directly in companies. Edmond de Rothschild Private Equity is based in Geneva, Switzerland.
| Deal Context for Seller | # |
|---|---|
| Overall | 11 of 27 |
| Sector: Test/Measurement Equipment | 2 of 2 |
| Type: Add-on Acquisition | 3 of 10 |
| Country: France | 8 of 20 |
| Year: 2015 | 1 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-12-18 |
OncoEthix SA
Lausanne, Switzerland OncoEthix is a privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The Company’s lead product, OTX015, is an investigational orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of Phase I clinical studies in healthy volunteers. |
Sell | $110M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-02-11 |
GlycoVaxyn AG
Schlieren, Switzerland GlycoVaxyn AG is a specialist vaccine biopharmaceutical company. |
Sell | $190M |
